Jiangsu Hengrui Pharmaceuticals (600276.SH): Sodium citrate blood filtration replacement solution approved for market launch.
Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has recently received a national ...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceuticals Co., Ltd., has received notification from the National Medical Products Administration (NMPA) approving the listing of sodium citrate blood filtration replacement solution.
Approved indications: This product can be used as a replacement solution for continuous renal replacement therapy (CRRT) using local citrate anticoagulation. Citrate is particularly suitable for cases where systemic anticoagulation with heparin is contraindicated, such as in patients at increased risk of bleeding. If equipment matching the weight of pediatric patients can be used, this product is suitable for children of all ages.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
